Extract
We hypothesise that inflammation plays a role in idiopathic pulmonary fibrosis (IPF) and that the harm associated with corticosteroid-containing regimens in IPF may relate to local beneficial effects being counterbalanced by deleterious systemic effects [1, 2]. Topical lung delivery could improve the poise between risk and benefit.
Abstract
IPF biomarker improved by ICS/LABA http://ow.ly/CHub30gzHry
Acknowledgements
A.H. Morice, S.P. Hart and M.G. Crooks conceived and designed the study; K. Brindle, C.E. Wright and S.D. Fraser acquired the data during the study, and S.D. Fraser, C.E. Wright, A.H. Morice, S.P. Hart, M.G. Crooks analysed and interpreted those data; C.E. Wright, A.H. Morice, S.P. Hart and M.G. Crooks drafted the manuscript, and all authors critically reviewed it and approved the submitted version.
Footnotes
This trial is registered at eudract.ema.europa.eu with identifer number 2013-004404-19
Support statement: This research was funded by Chiesi Ltd. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflicts of interest: Disclosures can be found alongside this article at openres.ersjournals.com
- Received August 14, 2017.
- Accepted October 20, 2017.
- Copyright ©ERS 2017
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.